Relative hazards (RH) (risk for death) and 3 year survival in patients treated for NSCLC between 1995 and 1999 (n = 466)
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| No (%) of patients | Percentage 3 year survival (95% CI) | RH | (95% CI) | RH | (95% CI) | |
| *Associated with an increase by one unit in the logarithm of age in years. | ||||||
| †With or without other treatment. | ||||||
| ‡Missing (n = 53). | ||||||
| §Associated with an increase by one unit in the logarithm of delay per month. | ||||||
| ¶Missing (n = 112). | ||||||
| Sex | ||||||
| Male | 268 (58) | 32 (26 to 39) | 1.0 | Reference | 1.0 | Reference |
| Female | 198 (42) | 31 (25 to 36) | 1.0 | (0.8 to 1.2) | 1.1 | (0.9 to 1.3) |
| Age | ||||||
| <70 years | 307 (66) | 31 (26 to 37) | 1.0 | Reference | 1.0 | Reference |
| ⩾70 years | 159 (34) | 31 (24 to 39) | 1.0 | (0.8 to 1.2) | 1.3 | (1.1 to 1.5) |
| Logarithmic (per year)* | – | – | 1.3 | (0.6 to 2.1) | 2.6 | (1.9 to 3.3) |
| Squamous cell cancer | ||||||
| No | 314 (67) | 27 (22 to 32) | 1.0 | Reference | 1.0 | Reference |
| Yes | 152 (24) | 39 (32 to 48) | 0.7 | (0.4 to 0.9) | 0.8 | (0.6 to 1.1) |
| Stage | ||||||
| I–II | 143 (31) | 69 (61 to 76) | 1.0 | Reference | 1.0 | Reference |
| IIIA | 37 (8) | 41 (25 to 56) | 3.0 | (0.8 to 5.1) | 1.9 | (1.4 to 2.4) |
| IIIB | 157 (34) | 16 (10 to 22) | 5.4 | (2.1 to 8.7) | 2.7 | (2.3 to 3.1) |
| IV | 129 (28) | 6 (2 to 10) | 9.6 | (5.2 to 14.1) | 4.5 | (4.1 to 4.9) |
| Surgical treatment | ||||||
| No | 315 (68) | 14 (10 to 17) | 1.0 | Reference | 1.0 | Reference |
| Yes† | 151 (33) | 69 (61 to 76) | 0.2 | (0.02 to 0.5) | 0.5 | (0.1 to 0.8) |
| Hospital delay‡ | ||||||
| <1 month | 112 (27) | 19 (12 to 28) | 1.0 | Reference | 1.0 | Reference |
| 1–2 months | 155 (38) | 34 (26 to 41) | 0.8 | (0.5 to 1.0) | 1.0 | (0.8 to 1.3) |
| 2–3 months | 78 (19) | 36 (25 to 46) | 0.7 | (0.4 to 0.9) | 0.9 | (0.6 to 1.3) |
| >3 months | 68 (16) | 43 (31 to 55) | 0.6 | (0.3 to 0.9) | 0.8 | (0.6 to 1.2) |
| Logarithmic (per month)§ | – | – | 0.75 | (0.6 to 0.8) | 0.98 | (0.8 to 1.1) |
| Symptom to treatment delay¶ | ||||||
| <3 months | 93 (26) | 11 (5 to 17) | 1.0 | Reference | 1.0 | Reference |
| 3–6 months | 139 (39) | 31 (23 to 39) | 1.0 | (0.7 to 1.2) | 0.9 | (0.7 to 1.2) |
| >6 months | 122 (35) | 35 (26 to 43) | 0.9 | (0.6 to 1.1) | 0.8 | (0.6 to 1.1) |
| Logarithmic (per month) | – | – | 0.65 | (0.4 to 0.8) | 0.80 | (0.6 to 1.0) |